{
    "root": "dd0346e2-5ff3-4208-ad88-d09182684603",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Ursodiol"
    },
    "value": "20250306",
    "ingredients": [
        {
            "name": "URSODIOL",
            "code": "724L30Y2QR"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        }
    ],
    "indications": "ursodiol capsules indicated patients radiolucent , noncalcified gallbladder stones < 20 mm greatest diameter elective cholecystectomy would undertaken except presence increased surgical risk due systemic disease , advanced age , idiosyncratic reaction general anesthesia , patients refuse surgery . safety ursodiol capsules beyond 24 months established . ursodiol capsules indicated prevention gallstone formation obese patients experiencing rapid weight loss .",
    "contraindications": "gallstone dissolution recommended dose ursodiol capsules treatment radiolucent gallbladder stones 8 10 mg/kg/day given 2 3 divided doses . ultrasound images gallbladder obtained 6-month intervals first year ursodiol capsules therapy monitor gallstone response . gallstones appear dissolved , ursodiol capsules therapy continued dissolution confirmed repeat ultrasound examination within 1 3 months . patients eventually achieve complete stone dissolution show partial complete dissolution first on-treatment reevaluation . partial stone dissolution seen 12 months ursodiol capsules therapy , likelihood success greatly reduced . gallstone prevention recommended ursodiol capsules gallstone prevention patients undergoing rapid weight loss 600 mg/day ( 300 mg b.i.d . ) .",
    "warningsAndPrecautions": "ursodiol capsules , usp 300 mg pink opaque cap white opaque body , hard gelatin capsules filled white white powder , imprinted ‘ uroh ’ cap ‘ 300 ’ body . available follows : bottles 100 ndc 72603-613-01 store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . dispense tight container ( usp ) . manufactured : northstar rx llc memphis , tn 38141. manufactured : apl health care limited , unit-i sez , mahabubnagar ( dt ) -509302 india . m.l.no . : 16/mn/ts/2014/f/g issued : 02/2025",
    "adverseReactions": "ursodiol capsules dissolve calcified cholesterol stones , radiopaque stones , radiolucent bile pigment stones . hence , patients stones candidates ursodiol capsules therapy . patients compelling reasons cholecystectomy including unremitting acute cholecystitis , cholangitis , biliary obstruction , gallstone pancreatitis , biliary-gastrointestinal fistula candidates ursodiol capsules therapy . allergy bile acids .",
    "indications_original": "Ursodiol capsules are indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of ursodiol capsules beyond 24 months is not established.\n                     Ursodiol capsules are indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss.",
    "contraindications_original": "Gallstone Dissolution\n                  \n                  The recommended dose for ursodiol capsules treatment of radiolucent gallbladder stones is 8 to 10 mg/kg/day given in 2 or 3 divided doses.\n                  \n                  Ultrasound images of the gallbladder should be obtained at 6-month intervals for the first year of ursodiol capsules therapy to monitor gallstone response. If gallstones appear to have dissolved, ursodiol capsules therapy should be continued and dissolution confirmed on a repeat ultrasound examination within 1 to 3 months. Most patients who eventually achieve complete stone dissolution will show partial or complete dissolution at the first on-treatment reevaluation. If partial stone dissolution is not seen by 12 months of ursodiol capsules therapy, the likelihood of success is greatly reduced.\n                     \n                     Gallstone Prevention\n                     \n                      The recommended dosage of ursodiol capsules for gallstone prevention in patients undergoing rapid weight loss is 600 mg/day (300 mg b.i.d.).",
    "warningsAndPrecautions_original": "Ursodiol Capsules, USP 300 mg are pink opaque cap and white opaque body, hard gelatin capsules filled with white to off white powder, imprinted with ‘UROH’ on cap and ‘300’ on body. They are available as follows:\n                  \n                  Bottles of 100                         NDC 72603-613-01\n                  \n                  \n                     Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].\n                  \n                  Dispense in a tight container (USP).\n                  \n                  Manufactured for: Northstar Rx LLC\n                                              Memphis, TN 38141.\n                  Manufactured by: APL Health Care Limited, Unit-I\n                                                SEZ, Mahabubnagar (Dt)-509302\n                                                India.\n                  M.L.No.: 16/MN/TS/2014/F/G\n                  Issued: 02/2025",
    "adverseReactions_original": "Ursodiol capsules will not dissolve calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment stones. Hence, patients with such stones are not candidates for ursodiol capsules therapy.\n                     Patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula are not candidates for ursodiol capsules therapy.\n                     Allergy to bile acids."
}